Key Takeaways
- • Atlas Venture closed its third Opportunity Fund at $400 million, an oversubscribed raise, according to a Business Wire announcement.
- • Opportunity Fund III will provide follow-on growth capital to existing Atlas-backed biotech companies in subsequent private and public financings.
- • The raise follows Atlas' $450 million Fund XIV, its latest early-stage vehicle, which closed in December 2024.
- • The general partners of Opportunity Fund III are Kevin Bitterman, Bruce Booth, Michael Gladstone, and Jason Rhodes.
Summary
Atlas Venture, a Cambridge, Massachusetts-based biotech venture capital firm, has announced the closing of its third Opportunity Fund, raising $400 million in an oversubscribed fundraise, according to a Business Wire release. The vehicle is designed to give Atlas longitudinal capital for its portfolio companies as they raise subsequent financings and advance therapeutic programs.
The Opportunity Fund III closing follows Atlas' $450 million Fund XIV, its latest early-stage vehicle, which closed in December 2024. The firm describes a two-fund model: early-stage capital from its core funds backs seed and Series A investments, with entrepreneurs-in-residence helping form and incubate new biotech companies around science sourced globally. The Opportunity Fund provides dedicated pools of growth capital for later-stage private and public financings of existing portfolio companies, paired with ongoing strategic involvement.
In a joint statement from the Atlas partnership, the firm said it had been encouraged by portfolio progress despite challenges facing biotechs in the current environment. The firm said the fund reinforces its commitment to raising funds tailored in size and strategy to its bespoke investment approach, and thanked its longstanding limited partners.
The general partners of Opportunity Fund III are Kevin Bitterman, Bruce Booth, Michael Gladstone, and Jason Rhodes. Jean-François Formela and David Grayzel continue as partners at the firm. Atlas says it has more than three decades of experience building biotechnology companies.
The Opportunity Fund III closing follows Atlas' $450 million Fund XIV, its latest early-stage vehicle, which closed in December 2024. The firm describes a two-fund model: early-stage capital from its core funds backs seed and Series A investments, with entrepreneurs-in-residence helping form and incubate new biotech companies around science sourced globally. The Opportunity Fund provides dedicated pools of growth capital for later-stage private and public financings of existing portfolio companies, paired with ongoing strategic involvement.
In a joint statement from the Atlas partnership, the firm said it had been encouraged by portfolio progress despite challenges facing biotechs in the current environment. The firm said the fund reinforces its commitment to raising funds tailored in size and strategy to its bespoke investment approach, and thanked its longstanding limited partners.
The general partners of Opportunity Fund III are Kevin Bitterman, Bruce Booth, Michael Gladstone, and Jason Rhodes. Jean-François Formela and David Grayzel continue as partners at the firm. Atlas says it has more than three decades of experience building biotechnology companies.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.